In a new consensus statement, the European Society of Cardiology has declared vaccinations for common infections to be a ...

A new ESC Clinical Consensus Statement published in the European Heart Journal discusses the key role of vaccination in ...

The VARIPULSE™ Platform is the first Pulsed Field Ablation (PFA) system fully integrated with the CARTO™ 3 electroanatomical mapping system, designed to drive efficiency, reproducibility, and ...

Dr Joseph A Hill discusses the diagnosis and management of heart failure with preserved ejection fraction (HFpEF).

Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

A new combination of inputs for the estimation of left ventricular filling pressure has shown to outperform those from ...

Discover how MemorialCare's Women's Heart Center at Long Beach is tackling the leading killer of women, heart disease, ...

BACKGROUND: Fontan circulatory failure (FCF) is a chronic state in palliated single ventricle heart disease with high morbidity and mortality rates, including heart failure, multisystem end-organ ...

Bayer and Merck & Co’s heart failure drug vericiguat has been approved by the FDA under the brand name Verquvo, in an increasingly competitive market.

The FDA has approved a new use for AstraZeneca’s Farxiga (dapagliflozin) to reduce risk of cardiovascular death and hospitalisation with heart failure, in adults with reduced ejection fraction ...

BACKGROUND: Primary aldosteronism (PA), an overt form of renin-independent aldosterone production, leads to a disproportionately high rate of major adverse cardiovascular events (MACEs). Mounting ...